Agios PharmaceuticalsFRA:8AP -3.13%44 Days Payable is 1,102.28 as of Mar. 2026, which is 39% below its 10-year median of 1,798.77. GuruFocus rates FRA:8AP with a GF Score™ of 44/100 and a GF Value™ of €67.84 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 706 Biotechnology companies, Agios Pharmaceuticals ranks better than 85.13% on this metric.
The historical rank and industry rank for Agios Pharmaceuticals's Days Payable or its related term are showing as below:
FRA:8AP'
s Days Payable Range Over the Past 10 Years
Min: 920 Med: 1798.77 Max: 5310.01
Current: 920
During the past 13 years, Agios Pharmaceuticals's highest Days Payable was 5310.01. The lowest was 920.00. And the median was 1798.77.
FRA:8AP's Days Payable is ranked better than 85.13% of 706
companies
in the Biotechnology industry
Industry Median: 113.56
vs FRA:8AP: 920.00
Agios Pharmaceuticals's Days Payable
declined
from Mar. 2025 (1,299.27) to Mar. 2026 (1,102.28).
It may suggest that Agios Pharmaceuticalsaccelerated paying its suppliers.
Agios Pharmaceuticals Days Payable Related Terms
Agios Pharmaceuticals Days Payable Historical Data
* Premium members only.
The historical data trend for Agios Pharmaceuticals's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:8AP vs ABCL, KOD, IMNM: Days Payable Comparison
For the Biotechnology subindustry, Agios Pharmaceuticals's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Agios Pharmaceuticals Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Agios Pharmaceuticals's Days Payable distribution charts can be found below:
* The bar in red indicates where Agios Pharmaceuticals's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Agios Pharmaceuticals's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Agios Pharmaceuticals (FRA:8AP) has a Days Payable of 1,102.28 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Agios Pharmaceuticals and its competitors. This is 39% below median its historical median of 1,798.77. Over the past decade, Agios Pharmaceuticals' Days Payable has ranged from 920.00 to 5,310.01. According to the industry distribution chart, Agios Pharmaceuticals ranks #105 out of 706 companies in the Biotechnology industry, placing it in the top 14.9%.
Is Agios Pharmaceuticals' Days Payable too high?
Agios Pharmaceuticals' current Days Payable of 1,102.28 is 39% below median its 10-year median of 1,798.77. Over the past 10 years, this metric has ranged from a low of 920.00 to a high of 5,310.01. The Biotechnology industry median Days Payable is 113.56. Agios Pharmaceuticals' value of 1,102.28 is 870.7% above this industry median. Based on the distribution chart, Agios Pharmaceuticals ranks #105 out of 706 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Agios Pharmaceuticals has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Agios Pharmaceuticals' Days Payable compare to ABCL and KOD?
According to the Biotechnology industry distribution chart, Agios Pharmaceuticals ranks #105 out of 706 companies for Days Payable. This places Agios Pharmaceuticals in the top 15% of its industry — outperforming the majority of peers. The industry median Days Payable is 113.56. Agios Pharmaceuticals' value of 1,102.28 is 870.7% above this benchmark. Historically, Agios Pharmaceuticals' own Days Payable has ranged from 920.00 to 5,310.01 over the past decade. While the company's 10-year median is 1,798.77 vs. the industry median of 113.56, Agios Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.56, based on 706 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Agios Pharmaceuticals's current Days Payable of 1,102.28 is 870.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Agios Pharmaceuticals and its competitors. For the Biotechnology industry, the median Days Payable is 113.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Agios Pharmaceuticals's current Days Payable is 1,102.28, which is 39% below median its own 10-year median of 1,798.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Agios Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Agios Pharmaceuticals (FRA:8AP) is currently considered Possible Value Trap. The stock's GF Value™ is €67.84, compared to a current price of €31.00 — trading 54.3% below its estimated fair value. The current Days Payable is 1,102.28, which is 39% below median its 10-year median of 1,798.77 and 870.7% above the Biotechnology industry median of 113.56. Agios Pharmaceuticals' overall GF Score™ is 44/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Agios Pharmaceuticals (FRA:8AP), the current Days Payable is 1,102.28 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Agios Pharmaceuticals (FRA:8AP) Overvalued in 2026?
Based on GuruFocus' analysis, Agios Pharmaceuticals stock appears to be undervalued.
The current stock price of €31.00 is trading 54.3% below its estimated GF Value™ of €67.84.
GuruFocus considers Agios Pharmaceuticals to be Possible Value Trap.
Key valuation signals for FRA:8AP:
Days Payable: 1,102.28 (39% below median its 10-year median of 1,798.77)
GF Value™: €67.84 vs. price of €31.00 (54.3% below fair value)
Industry Position: 870.7% above the Biotechnology median (#105 of 706)
No single metric tells the full story. See the FRA:8AP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
44GF Score
Get the complete analysis for FRA:8AP
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:8AP has been successfully added to your 
